Alicia D. Greenidge, Director General, IFPMA WHO Expert Working Group, Geneva, 12 Jan 2009. IFPMA Presentation to WHO Expert Working Group on Funding R&D for Diseases of the Developing World (DDW). Tackling DDWs: a Combined Effort…. Access (incl. Delivery). Basic Research. - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Alicia D. Greenidge, Director General, IFPMAAlicia D. Greenidge, Director General, IFPMAWHO Expert Working Group, Geneva, 12 Jan 2009WHO Expert Working Group, Geneva, 12 Jan 2009
IFPMA Presentation to WHO Expert Working Group on IFPMA Presentation to WHO Expert Working Group on Funding R&D for Diseases of the Developing World (DDW)Funding R&D for Diseases of the Developing World (DDW)
(Current industry involvement & partnerships - illustrative only - not comprehensive)(Current industry involvement & partnerships - illustrative only - not comprehensive)
R&D for a New Medicine: 10+ years, $1 bn+R&D for a New Medicine: 10+ years, $1 bn+
Sources: Drug Discovery and Development: Understanding the R&D Process, www.innovation.org; CBO, Research and Development in the Pharmaceutical Industry, 2006(1) incl. cost of capital – from The price of innovation: new estimates of drug development costs, DiMasi et al, Tufts Center for the Study of Drug Development, 2002
… … a big challenge for addressing both developed and developing world diseasesa big challenge for addressing both developed and developing world diseases
$335 million $335 million (1)(1) $467 million $467 million (1)(1)
Industry R&D for DDW is GrowingIndustry R&D for DDW is Growing
32
43
6
50
8
58
9
0
10
20
30
40
50
60
2005 2006 2007 2008
Num
ber o
f Act
ive
R&
D P
roje
cts
Num
ber o
f Act
ive
R&
D P
roje
cts
Sources: 2005 - Moran et Al “New Landscape…” 2006, 2007, 2008 – IFPMA Status ReportsSources: 2005 - Moran et Al “New Landscape…” 2006, 2007, 2008 – IFPMA Status Reports
# R&D Projects by IFPMA Companies, with Product Development Partnerships or alone# R&D Projects by IFPMA Companies, with Product Development Partnerships or alone
1 project = 1 compound in development 1 project = 1 compound in development OR 1 screening program for 1 diseaseOR 1 screening program for 1 disease
Industry DDW R&D is Increasingly CollaborativeIndustry DDW R&D is Increasingly Collaborative
Sources: 2005 - Moran et Al “New Landscape…” 2006, 2007, 2008 – IFPMA Status ReportsSources: 2005 - Moran et Al “New Landscape…” 2006, 2007, 2008 – IFPMA Status Reports
Companies working aloneCompanies working alone
Companies working with PDPsCompanies working with PDPs
# Medicine & Vaccine R&D Projects by IFPMA Companies, with PDPs or alone# Medicine & Vaccine R&D Projects by IFPMA Companies, with PDPs or alone
Bringing partners together over the last decade…Bringing partners together over the last decade…
World Bank
Rockefeller
Bill & Melinda Gates
Wellcome TrustUSAID
DFID
PEPFAR
PMI
Grand Challenges
CIDA
Global Fund
GAVI
Doris Duke
Clinton Foundation
Carter Center
Basic Research OrganizationsBasic Research Organizations
TB medicines2000
TB treatments1998
Hookworm vaccines2000
Rotavirus vaccines2003
Pneumonia vaccines2003
Malaria, rotavirus, JE, pneumococcal & meningitis vaccines
1977
Malaria vaccines1999
Malaria medicines2000
Dengue vaccines2003
VL, malaria, diarrhoea& STH medicines2000
HAT, VL, Chagas & malaria medicines2003
TB vaccines2003
FocusFocusSinceSincePDPPDP
FundersFunders Product Development PartnershipsProduct Development Partnerships R&D ExecutionR&D Execution
(Funders, PDPs, Basic Research Organizations & Industry Players - illustrative only - not comprehensive)(Funders, PDPs, Basic Research Organizations & Industry Players - illustrative only - not comprehensive)
Some DDWs are More Neglected than OthersSome DDWs are More Neglected than Others
(HAT = Human African Trypanosomiasis or “Sleeping Sickness”)(HAT = Human African Trypanosomiasis or “Sleeping Sickness”)
Some “More Neglected Diseases” need R&D Some “More Neglected Diseases” need R&D more urgently than others and should be prioritized more urgently than others and should be prioritized
4 Approved Meds: ALL intravenous or intramuscular, 3 are v. old4 Approved Meds: ALL intravenous or intramuscular, 3 are v. old
0 Approved Meds0 Approved Meds
2 Approved Meds: 1) intravenous & side effects 2) v. expensive2 Approved Meds: 1) intravenous & side effects 2) v. expensive
2 Approved Meds: BOTH less effective against fatal late stage2 Approved Meds: BOTH less effective against fatal late stage
1 Approved Med: Effective, large donation program. Resistance?1 Approved Med: Effective, large donation program. Resistance?
3 Approved Meds: Effective, large donation program3 Approved Meds: Effective, large donation program
3 Approved Meds: Effective, large donation program3 Approved Meds: Effective, large donation program
1 Approved Med: Effective, large donation program1 Approved Med: Effective, large donation program
Source: 2008 IFPMA Status ReportSource: 2008 IFPMA Status Report
Current DDW R&D Funding will be InsufficientCurrent DDW R&D Funding will be Insufficient as Pipelines Advance as Pipelines Advance
Dalberg Study for IFPMA (2007)Dalberg Study for IFPMA (2007) Total Funding for PDPs to 2007 = USD 0.5 billionTotal Funding for PDPs to 2007 = USD 0.5 billion Est. funding to take current PDP pipelines to approval AND to augment Est. funding to take current PDP pipelines to approval AND to augment
inadequate pipelines for Most Neglected Diseases = USD 8.3 billioninadequate pipelines for Most Neglected Diseases = USD 8.3 billion
Estimated funding needs profile for Neglected diseases R&D drugs – 2008-2017USD B
Sources: Global plan to Stop TB 2006-2015; MMV financial plan 2008-2017; DNDi Business plan 2007-2014; Dalberg interviews and analysis.
0.4
2009
0.6
2010
0.9
2011
1.0
2012
1.1
2013
1.2
2014
1.1
2015
1.5
0.3
2008
1.0
2016
0.8
2017
Other diseasesHAT/ VL/ ChagasMalaria
TB
0.0
1.0
0.5
Mid-range funding need for the next 10 years
USD 8.3 B
Source: Dalberg for IFPMASource: Dalberg for IFPMA
All stages of the value chain – VL, Chagas, HAT(3)
Full Portfolio management with Fund
Partial Portfolio management with Fund
Pre-selection of intermediaries / recipients
All intermediaries - All recipients
Firm RecommendationFirm Recommendation
Initial recommendationInitial recommendation
OptionsOptions
Sustainable Funding
Push financing – spot commitments
Push financing – long term commitments
Push financing – IFF mechanism
Funding Prioritization
Spreading
Picking winners
Impact based sequence
Success based sequence
Notes: Notes: (1) TDR: WHO Special Programme for Research and Training in Tropical Diseases(1) TDR: WHO Special Programme for Research and Training in Tropical Diseases(2) NTD: WHO Control of Neglected Tropical Disease programme(2) NTD: WHO Control of Neglected Tropical Disease programme(3) Clinical trials only for Malaria and TB, discovery only for other diseases without existing PDPs, all stages of the value (3) Clinical trials only for Malaria and TB, discovery only for other diseases without existing PDPs, all stages of the value
chain for other diseases with existing PDPschain for other diseases with existing PDPs
Study Also Looked at Sustainable Funding StructureStudy Also Looked at Sustainable Funding Structure
Source: Dalberg for IFPMASource: Dalberg for IFPMA
Enhanced Industry Contribution: Potential Next Steps Enhanced Industry Contribution: Potential Next Steps
Consult with WHO & other partners to prioritize DDW R&D needsConsult with WHO & other partners to prioritize DDW R&D needs
Explore working with African Network for Drugs Discovery & Explore working with African Network for Drugs Discovery & Innovation (ANDI)Innovation (ANDI)
IFPMA working on a Developing Country Young Researcher AwardIFPMA working on a Developing Country Young Researcher Award
IFPMA exploring ways to facilitate IFPMA exploring ways to facilitate increased availability of industry increased availability of industry resourcesresources
IFPMA Members looking at additional activities in partnership with IFPMA Members looking at additional activities in partnership with DNDi DNDi et alet al
Consulting on other possible collaborationsConsulting on other possible collaborations
ConclusionsConclusions DDW R&D has increased substantiallyDDW R&D has increased substantially
• Increased activity by Product Development PartnershipsIncreased activity by Product Development Partnerships
• Increased in-kind & not-for-profit contribution by industryIncreased in-kind & not-for-profit contribution by industry
Current DDW R&D is mainly in less expensive earlier stagesCurrent DDW R&D is mainly in less expensive earlier stages• Funding requirements will increase as more projects move into clinical trialsFunding requirements will increase as more projects move into clinical trials
Industry is working to help expand and improve current DDW effortIndustry is working to help expand and improve current DDW effort Current volume of DDW R&D inadequate to deliver enough new Current volume of DDW R&D inadequate to deliver enough new
medicines for all the most needy diseasesmedicines for all the most needy diseases• Shortfall is significant – funding to date perhaps 10 % of what is neededShortfall is significant – funding to date perhaps 10 % of what is needed
Additional funding critical to achieve adequate range of new Additional funding critical to achieve adequate range of new medicines & vaccines for Most Neglected Diseasesmedicines & vaccines for Most Neglected Diseases